My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 140

    1.

    Responding to the rofecoxib withdrawal crisis: a new model for notifying patients at risk and their health care providers.

    Jain A, Atreja A, Harris CM, Lehmann M, Burns J, Young J.

    Ann Intern Med. 2005 Feb 1;142(3):182-6.PMID: 15684206 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Using information technology to transfer knowledge: a medical institution steps up to the plate.

    Badgett R, Mulrow C.

    Ann Intern Med. 2005 Feb 1;142(3):220-1. No abstract available. PMID: 15684213 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Ten lessons to be learned from the withdrawal of Vioxx (rofecoxib).

    Carné X, Cruz N.

    Eur J Epidemiol. 2005;20(2):127-9. No abstract available. PMID: 15792277 [PubMed - indexed for MEDLINE]Related articles

    4.

    [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences]

    van der Veen WJ, van der Werf GT.

    Ned Tijdschr Geneeskd. 2006 May 6;150(18):1016-21. Dutch. PMID: 16715866 [PubMed - indexed for MEDLINE]Related articles

    5.

    Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.

    Nettis E, Colanardi MC, Ferrannini A, Tursi A.

    Ann Allergy Asthma Immunol. 2005 Jan;94(1):29-33.PMID: 15702812 [PubMed - indexed for MEDLINE]Related articles

    6.

    The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.

    Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.

    Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):437-41. Erratum in: Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):669. PMID: 15937867 [PubMed - indexed for MEDLINE]Related articles

    7.

    Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.

    Hudson M, Richard H, Pilote L.

    BMJ. 2005 Jun 11;330(7504):1370.PMID: 15947399 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.

    Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A.

    Ann Allergy Asthma Immunol. 2005 Jan;94(1):34-8.PMID: 15702813 [PubMed - indexed for MEDLINE]Related articles

    9.

    [The withdrawal of Vioxx: how did the patients react?]

    Rognstad S, Straand J.

    Tidsskr Nor Laegeforen. 2006 May 11;126(10):1326-7. Norwegian. PMID: 16691268 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.

    Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Nørgård B, Friis S, Sørensen HT.

    Arch Intern Med. 2005 May 9;165(9):978-84.PMID: 15883235 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.

    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.

    Lancet. 2005 Feb 5-11;365(9458):475-81.PMID: 15705456 [PubMed - indexed for MEDLINE]Related articles

    12.

    [Evaluation model of the effect of Rofecoxib on the co-prescription of gastroprotective agents observed during the treatment of osteoarthritis]

    Russo P, Capone A, Baio G, Di Martino M, Degli Esposti L, Buda S, Degli Esposti E, Caprino L.

    Reumatismo. 2002 Oct-Dec;54(4):331-9. Italian. PMID: 12563367 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Large-scale stopping and switching treatment with COX-2 inhibitors after the rofecoxib withdrawal.

    Sukel MP, van der Linden MW, Chen C, Erkens JA, Herings RM.

    Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):9-19.PMID: 17963198 [PubMed - indexed for MEDLINE]Related articles

    14.

    A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data.

    Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA.

    Drug Saf. 2005;28(9):803-16.PMID: 16119973 [PubMed - indexed for MEDLINE]Related articles

    15.

    Lessons on prescribing and drug safety from the withdrawal of rofecoxib.

    Nelson M, Cicuttini F.

    Aust Fam Physician. 2004 Dec;33(12):965-6. No abstract available. PMID: 15630913 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Rofecoxib (Vioxx) withdrawal: do product monographs adequately inform physicians?

    [No authors listed]

    Can Fam Physician. 2005 Feb;51:212-3. English, French. No abstract available. PMID: 15751564 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    A double-blind prospective comparison of rofecoxib vs ketorolac in reducing postoperative pain after arthroscopic knee surgery.

    Kim JT, Sherman O, Cuff G, Leibovits A, Wajda M, Bekker AY.

    J Clin Anesth. 2005 Sep;17(6):439-43.PMID: 16171664 [PubMed - indexed for MEDLINE]Related articles

    18.

    Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.

    N Engl J Med. 2005 Mar 17;352(11):1092-102. Epub 2005 Feb 15. Erratum in: N Engl J Med. 2006 Jul 13;355(2):221. PMID: 15713943 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Prescribing pattern of drugs in the treatment of osteoarthritis in Italian general practice: the effect of rofecoxib withdrawal.

    Alacqua M, Trifirò G, Cavagna L, Caporali R, Montecucco CM, Moretti S, Tari DU, Galdo M, Caputi AP, Arcoraci V.

    Arthritis Rheum. 2008 Apr 15;59(4):568-74.PMID: 18383398 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Adverse oral reactions associated with the COX-2 inhibitor rofecoxib.

    Bagán JV, Thongprasom K, Scully C.

    Oral Dis. 2004 Nov;10(6):401-3.PMID: 15533219 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity